Brendan P Eckelman

This inventor holds 48 USPTO granted patents and 37 published patent applications, plus 6 CIPO patents and 6 EPO patents, primarily in Monoclonal Antibodies. Top assignees: Inhibrx, Inc., Inhibrx Biosciences, Inc., Oxford Finance LLC. Active years: 2015-2026.

USPTO Granted Patents = 48 (Patent Applications = 37)

% Patents Active = 100.0

CIPO Patents = 6 (Patent Applications = 33)

EPO Patents = 6 (Patent Applications = 42)

Average Co-Inventor Count = 5.5

ph-index = 6

Forward Citations = 152(Granted Patents)

Location History:

San Diego, CA (US) (2017 - 2022)
La Jolla, CA (US) (2015 - 2024)
Encinitas, CA (US) (2017 - 2024)

Company Filing History:

Inhibrx Biosciences, Inc.

Elanco Tiergesundheit Ag

Phylaxis Bioscience, LLC

patent

7. 1 out of 1,479

Regeneron Pharmaceuticals, Inc.

patents

where one patent can have more than one assignee

Years Active: 2015-2026

Loading Chart...

Areas of Expertise:

Monoclonal Antibodies

Single Domain Antibodies

Immunotherapies

Multispecific Constructs

OX40-binding Polypeptides

CD33-targeted Therapies

PD-1 Antibodies

Serpin Fusion Polypeptides

Therapeutic Compositions

Multivalent Proteins

Binding Polypeptides

Type III Secretion System

48 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12600792 - MONOCLONAL ANTIBODIES AND METHODS OF USE (2026-04-14),

2. 12590169 - 5T4 SINGLE DOMAIN ANTIBODIES AND THERAPEUTIC COMPOSITIONS THEREOF (2026-03-31),

3. 12552855 - CD33 TARGETED IMMUNOTHERAPIES (2026-02-17),

4. 12522661 - CD28 SINGLE DOMAIN ANTIBODIES AND MULTIVALENT AND MULTISPECIFIC CONSTRUCTS THEREOF (2026-01-13),

5. 12421315 - CLL-1 targeted immunotherapies (2025-09-23),

6. 12365728 - DLL3 single domain antibodies and therapeutic compositions thereof (2025-07-22),

7. 12331132 - Multispecific polypeptide constructs having constrained CD3 binding and related methods and uses (2025-06-17),

8. 12331126 - OX40-binding polypeptides and uses thereof (2025-06-17),

9. 12297271 - PD-1 single domain antibodies and therapeutic compositions thereof (2025-05-13),

10. 12234297 - IgE binding proteins and uses thereof (2025-02-25),

11. 12227584 - Multivalent and multispecific OX40-binding fusion proteins (2025-02-18),

12. 12195533 - Multispecific polypeptide constructs containing a constrained CD3 binding domain and a receptor binding region and methods of using the same (2025-01-14),

13. 12187804 - Multivalent and multispecific 41BB-binding proteins (2025-01-07),

14. 12084502 - CD33-binding polypeptides and uses thereof (2024-09-10),

15. 12043667 - CLEC12a binding polypeptides and uses thereof (2024-07-23),

Title: The Innovative Contributions of Brendan P. Eckelman

Introduction

Brendan P. Eckelman is a prominent inventor based in La Jolla, California, recognized for his extensive contributions to the field of biochemistry and immunology. With a remarkable portfolio of 33 patents, Eckelman's work primarily revolves around innovative medical therapies and treatments aimed at enhancing immune response.

Latest Patents

Among Eckelman's latest patents are groundbreaking inventions such as "OX40-binding polypeptides and uses thereof." This patent introduces VHH-containing polypeptides that bind and activate the OX40 receptor, presenting significant potential for immunotherapy applications. Another noteworthy patent is focused on "Multivalent and multispecific DR5-binding fusion proteins and methods of modulating immune cells." This invention addresses molecules that engage death receptor 5 (DR5), facilitating the modulation of immune responses, crucial for cancer treatments.

Career Highlights

Brendan Eckelman has made significant strides in his career, working with esteemed companies in the biotechnology sector, including Inhibrx, Inc. and Elanco Tiergesundheit Ag. His role within these organizations has been pivotal in developing innovative therapies that aim to transform patient care in immunology.

Collaborations

Eckelman's success is also attributed to fruitful collaborations with notable individuals in his field. Some of his coworkers include respected professionals such as John C. Timmer and Quinn L. Deveraux, with whom he has shared insights and expertise to drive forward various research initiatives.

Conclusion

Brendan P. Eckelman exemplifies the spirit of innovation, continually pushing the boundaries of what is possible in medical science. His contributions not only elevate the standard of care for patients but also inspire future generations of inventors in the rapidly evolving landscape of biotechnology.